CoChat

Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis

Al Attar, Atef, Antaramian, Ani, Noureddin, Mazen · 2021 · Expert Review of Clinical Pharmacology

The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Galectin-3 (Gal-3) is a β-galactoside binding protein associated with many disease pathologies, including chronic inflammation and fibrogenesis. It has been implicated in the disease severity of NASH, although its precise role is unknown. Inhibition of Gal-3 has shown to improve and prevent fibrosis progression and has now reached phase III clinical trial in NASH patients. AREAS COVERED: This discusses the role of Gal-3 in NASH. It brings together the current findings of Gal-3 in NASH and hepatic fibrosis by analyzing recent data from animal model studies and clinical trials. EXPERT OPINION: Gal-3 inhibitors, in particular, Belapectin (GR-MD-02), have shown promising results for NASH with advanced fibrosis. In a phase 2 trial, Belapectin did not meet the primary endpoint. However, a sub-analysis of Belapectin among a separate group of patients without esophageal varices showed 2 mg/kg of GR-MD-02 reduced HVPG and the development of new varices. A subsequent study is under way, aiming to replicate the positive findings in phase 2 and demonstrate greater efficacy. If Belapectin is shown to be effective, it will be coupled with other drugs that target steatohepatitis to maximize efficacy and disease reversal.

Overview

Integrity signals

Registry

Crossref · 10.1080/17512433.2021.1894127

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 71 references

Research works printed but not linked: 2

  1. Petit JM, 2017, J Clin Endocrinol Metab, 102, 407
  2. Dong R, 2018, Int J Mol Med, 41, 599

Cited by

See all 48

Metadata

Authors
Al Attar, A., Antaramian, A., & Noureddin, M.
Affiliations
  • Karsh Division of Gastroenterology and Hepatology, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA
  • Cedars-Sinai Medical Center (US)
Corresponding author
Noureddin, Mazen
Venue
Expert Review of Clinical Pharmacology
Published
2021-03-02
Volume
14
Issue
4
Pages
457-464
ISSN
  • 1751-2433 (ISSN-L)
  • 1751-2441
OpenAlex
W3130635956
Cited by
47
References
71
Citations by year
2026: 2 · 2025: 12 · 2024: 11 · 2023: 9 · 2022: 12 · 2021: 1
FWCI
1.26
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Review of Clinical Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › Galectins and Cancer Biology
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
galectin-3, galectin-3 inhibitors, nonalcoholic steatohepatitis, liver fibrosis, esophageal varices, portal hypertension, chronic inflammation, combination therapy
MeSH terms
Animals, Blood Proteins, Disease Models, Animal, Humans, Liver Cirrhosis, Pectins, Severity of Illness Index, Disease Progression, Galectins, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis. https://app.cochat.ai/papers/10.1080/17512433.2021.1894127
The paper
Al Attar, A., Antaramian, A., & Noureddin, M. (2021). Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2021.1894127

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.